Back to Journals » Neuropsychiatric Disease and Treatment » Volume 5

Treatment of obese patients with binge eating disorder using topiramate: a review

Authors Leombruni P, Lavagnino L, Fassino S

Published 7 July 2009 Volume 2009:5 Pages 385—392


Review by Single anonymous peer review

Peer reviewer comments 5

Paolo Leombruni, Luca Lavagnino, Secondo Fassino

Department of Neurosciences, Psychiatry Section, University of Torino, Centre for Eating Disorders and Obesity, Torino, Italy

Abstract: Topiramate is an anticonvulsant drug used for the treatment of epilepsy and prophylaxis of migraine. Some authors have proposed its use as a mood stabilizer and have reported its efficacy in reducing impulsiveness and improving mood regulation, possibly via its antagonism to glutamatergic transmission in the lateral hypothalamus, although this indication is still controversial. Weight loss is a side effect consistently reported in the medical literature in patients treated with topiramate. Given its potential role in stabilizing mood and reducing impulse control problems and weight, topiramate has been proposed as a treatment for obese patients with binge eating disorder (BED). The aim of this paper is to review published data on the efficacy and safety of topiramate for the treatment of obese subjects with BED. Although the evidence is preliminary, topiramate appears to be a relatively safe and effective treatment for obese subjects with BED. Limitations of the studies and future directions for research are discussed.

Keywords: topiramate, binge eating disorder, obesity

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.